


hGAPDH-IN-1

Cat. No.:	HY-149076
Molecular Formula:	C ₁₂ H ₁₂ BrNO
Molecular Weight:	266.13
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	hGAPDH-IN-1, a 3-bromo-4,5-dihydroisoxazole derivative, is a specific and potent hGAPDH covalent inhibitor. hGAPDH-IN-1 reduces cancer cell growth in different pancreatic cancer cell lines.	
In Vitro	hGAPDH-IN-1 (compound 11; 1-100 μM; 48 hours) turns out to strongly reduce cancer cell growth in all tested cell lines ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay ^[1]	
	Cell Line:	PaCa-3, PaCa-44, PANC-1, and MIA PaCa-2 cell lines
	Concentration:	1, 2.5, 5, 10, 25, 50, 100 μM
	Incubation Time:	48 hours
	Result:	Turned out to strongly reduce cancer cell growth in all tested cell lines. Had IC ₅₀ s of 4.69 μM, 16.16 μM, 21.72 μM, 15.2 μM for PaCa-3, PaCa-44, PANC-1, and MIA PaCa-2 cell lines, respectively.

REFERENCES

[1]. Andrea Galbiati, et al. Discovery of a spirocyclic 3-bromo-4,5-dihydroisoxazole covalent inhibitor of hGAPDH with antiproliferative activity against pancreatic cancer cells. *Eur J Med Chem.* 2023 Apr 6;254:115286.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA